

Integrated Filing (Finance) Other than Bank

Hemant Surgical Industries Ltd

General Information

Scrip code*	543916
NSE Symbol*	NOTLISTED
MSEI Symbol*	NOTLISTED
ISIN*	INE0GYI01028
Type of company	SME
Class of security	Equity
Date of start of financial year	01-04-2025
Date of end of financial year	31-03-2026
Date of board meeting when results were approved	15-05-2026
Date on which prior intimation of the meeting for considering financial results was informed to the exchange	09-05-2026
Description of presentation currency	INR
Level of rounding	Lakhs
Reporting Type	Half Yearly
Reporting Quarter	Yearly
Nature of report standalone or consolidated	Standalone
Whether results are audited or unaudited for the quarter ended	Audited
Whether results are audited or unaudited for the Year to date for current period ended/year ended	Audited
Segment Reporting	Single segment
Description of single segment	Medical Equipnment & Supplies
Start date of board meeting	15-05-2026
Start time of board meeting	14:30:00
End date of board meeting	15-05-2026
End time of board meeting	16:05:00
Whether cash flow statement is applicable on company	Yes
Type of cash flow statement	Cash Flow Indirect
Declaration of unmodified opinion or statement on impact of audit qualification	Declaration of unmodified opinion
Whether the company has any related party?	Yes
Whether the company has entered into any Related Party transaction during the selected half year for which it wants to submit disclosure?	Yes
(I) We declare that the acceptance of fixed deposits by the bans/Non-Banking Finance Company are at the terms uniformly applicable/offered to all shareholders/public	NA
(II) We declare that the scheduled commercial bank, as per RBI circular RBI/DBR/2015-16/19 dated March 03, 2016, has allowed additional interest of one per cent per annum, over and above the rate of interest mentioned in the schedule of interest rates on savings or a term deposits of bank's staff and their exclusive associations as well as on deposits of Chairman, Chairman & Managing Director, Executive Director or such other Executives appointed for a fixed tenure.	NA
(III) Whether the company is a 'high value debt listed entity' according to regulation 15 (1A)?	No
(a) If answer to above question is Yes, whether complying with proviso to regulation 23 (9), i.e., submitting RPT disclosures on the day of results publication?	
(b) If answer to above question is No, please explain the reason for not complying.	
Whether the updated Related Party Transactions (RPT) Policy (in compliance with Reg. 23 of SEBI LODR) has been uploaded on the website of the Company?	Yes
Latest Date on which RPT policy is updated	15-05-2026

Company Results

Indicate Company website link for updated RPT policy of the Company	https://hemantsurgical.com/investor-relations/codes-policies	
Whether statement on deviation or variation for proceeds of public issue, rights issue, preferential issue, qualified institutions placement etc. is applicable to the company for the current quarter?	Yes	
No. of times funds raised during the quarter	1	
Whether the disclosure for the Default on Loans and Debt Securities is applicable to the entity?	No	Textual Information(1)

Text Block

Textual Information(1)	Not Applicable
--	----------------

Financial Results - Other than Bank

		Amount in (Lakhs)	
Particulars		3 months/ 6 months ended (dd-mm-yyyy)	Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period		01-10-2025	01-04-2025
Date of end of reporting period		31-03-2026	31-03-2026
Whether results are audited or unaudited		Audited	Audited
Nature of report standalone or consolidated		Standalone	Standalone
Part I	Blue color marked fields are non-mandatory. For Consolidated Results, if the company has no figures for 3 months / 6 months ended, in such case zero shall be inserted in the said column.		
1	Revenue From Operations		
	Revenue from operations	16,672.65	23,098.71
	Other income	339.30	572.73
	Total income	17,011.95	23,671.44
2	Expenses		
(a)	Cost of materials consumed	14,551.27	18,739.46
(b)	Purchases of stock-in-trade	0.00	0.00
(c)	Changes in inventories of finished goods, work-in-progress and stock-in-trade	(1,404.65)	(962.56)
(d)	Employee benefit expense	511.95	996.85
(e)	Finance costs	201.18	396.51
(f)	Depreciation and amortisation expense	78.89	152.18
(g)	Other Expenses		
1	Other Expenses	1,432.62	1,985.99
	Total other expenses	1,432.62	1,985.99
	Total expenses	15,371.26	21,308.43
3	Profit before exceptional and extraordinary items and tax	1,640.69	2,363.01
4	Exceptional items	0.00	0.00
5	Profit before extraordinary items and tax	1,640.69	2,363.01
6	Extraordinary items	0.00	0.00
7	Profit before tax	1,640.69	2,363.01
8	Tax Expense		
	Current tax	282.02	425.33
	Deferred tax	75.86	114.34
	Total tax expenses	357.88	539.67
9	Net Profit Loss for the period from continuing operations	1,282.81	1,823.34
10	Profit (loss) from discontinuing operations before tax	0.00	0.00
11	Tax expense of discontinuing operations	0.00	0.00
12	Net profit (loss) from discontinuing operation after tax	0.00	0.00
13	Profit (loss) for period before minority interest	1,282.81	1,823.34
14	Share of profit (loss) of associates		
15	Profit (loss) of minority interest		
16	Net profit (Loss) for the period	1,282.81	1,823.34
17	Details of equity share capital		
	Paid-up equity share capital	1,303.84	1,303.84
	Face value of equity share capital	10.00	10.00
18	Reserves excluding revaluation reserve		0.00
19	Earnings per equity share (for continuing and discontinued operations)		

Company Results

	Basic earnings (loss) per share from continuing and discontinued operations	10.85	15.42
	Diluted earnings (loss) per share from continuing and discontinued operations	10.54	14.98
20	Debt equity ratio		
21	Debt service coverage ratio		
22	Interest service coverage ratio		
23	Remarks for debt equity ratio		
24	Remarks for debt service coverage ratio		
25	Remarks for interest service coverage ratio		
26	Disclosure of notes on financial results		

Statement of Asset and Liabilities

Amount in (Lakhs)

Particulars	Year ended (dd-mm-yyyy)
Date of start of reporting period	01-04-2025
Date of end of reporting period	31-03-2026
Whether results are audited or unaudited	Audited
Nature of report standalone or consolidated	Standalone
Equity and liabilities	
1 Shareholders' funds	
Share capital	1,303.84
Reserves and surplus	11,412.67
Money received against share warrants	1,033.86
Total shareholders' funds	13,750.37
2 Share application money pending allotment	0.00
3 Deferred government grants	0.00
4 Minority interest	0.00
5 Non-current liabilities	
Long-term borrowings	288.36
Deferred tax liabilities (net)	0.00
Foreign currency monetary item translation difference liability account	0.00
Other long-term liabilities	
Total of other long-term liabilities	
Long-term provisions	63.99
Total non-current liabilities	352.35
6 Current liabilities	
Short-term borrowings	4,678.12
Trade Payables	
(A) Total outstanding dues of micro enterprises and small enterprises	226.39
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises	6,894.13
Total Trade payable	7,120.52
Other current liabilities	
1 Other Current Liabilities	1,125.76
Total of other current liabilities	1,125.76
Short-term provisions	373.61
Total current liabilities	13,298.01
Total equity and liabilities	27,400.73
Assets	
1 Non-current assets	
(i) Property, Plant and Equipment and Intangible assets	
Property, Plant and Equipment	5,339.64
Producing properties	0.00
Intangible assets	0.00
Preproducing properties	0.00
Property, Plant and Equipment capital work-in-progress	0.00
Intangible assets under development or work-in-progress	0.00
Total Property, Plant and Equipment and Intangible assets	5,339.64
(ii) Non-current investments	20.25

(v)	Deferred tax assets (net)	78.48
(vi)	Foreign currency monetary item translation difference asset account	0.00
(vii)	Long-term loans and advances	2,259.02
	Other non-current assets	
1	Other Non Current Assets	500.86
	Total of other non-current assets	500.86
	Total non-current assets	8,198.25
2	Current assets	
	Current investments	0.00
	Inventories	5,865.29
	Trade receivables	6,724.81
	Cash and cash equivalents	4,383.11
	Bank balance other than cash and cash equivalents	0.00
	Short-term loans and advances	908.79
	Other current assets	
1	Other Current Assets	1,320.48
	Total of other current assets	1,320.48
	Total current assets	19,202.48
	Total assets	27,400.73
	Disclosure of notes on assets and liabilities	

Cash flow statement indirect

Amount in (Lakhs)

Particulars	Year ended (dd-mm-yyyy)
Date of start of reporting period	01-04-2025
Date of end of reporting period	31-03-2026
Whether results are audited or unaudited	Audited
Nature of report standalone or consolidated	Standalone
1 Statement of cash flows	
Cash flows from used in operating activities	
Profit before extraordinary items and tax	2,363.01
2 Adjustments for reconcile profit (loss)	
Adjustments to profit (loss)	
Adjustments for finance costs	396.51
Adjustments for depreciation and amortisation expense	152.18
Adjustments for impairment loss reversal of impairment loss recognised in profit or loss	0.00
Adjustments for unrealised foreign exchange losses gains	0.00
Adjustments for dividend income	0.00
Adjustments for share-based payments	0.00
Other adjustments for which cash effects are investing or financing cash flow	0.00
Other adjustments to reconcile profit (loss)	0.00
Other adjustments for non-cash items	(91.88)
Share of profit and loss from partnership firm or association of persons or limited liability partnerships	0.00
Total adjustments to profit (loss)	456.81
3 Adjustments for working capital	
Adjustments for decrease (increase) in inventories	(1,617.78)
Adjustments for decrease (increase) in trade receivables	(4,693.66)
Adjustments for decrease (increase) in other current assets	(2,409.56)
Adjustments for increase (decrease) in trade payables	3,239.78
Adjustments for increase (decrease) in other current liabilities	64.89
Adjustments for provisions	0.00
Total adjustments for working capital	(5,416.33)
Total adjustments for reconcile profit (loss)	(4,959.52)
Net cash flows from (used in) operations	(2,596.51)
Dividends received	0.00
Interest paid	0.00
Interest received	(166.56)
Income taxes paid (refund)	439.20
Other inflows (outflows) of cash	0.00
Net cash flows from (used in) operating activities before extraordinary items	(3,202.27)
Proceeds from extraordinary items	0.00
Payment for extraordinary items	0.00
Net cash flows from (used in) operating activities	(3,202.27)
4 Cash flows from used in investing activities	
Cash flows from losing control of subsidiaries or other businesses	0.00
Cash flows used in obtaining control of subsidiaries or other businesses	0.00
Other cash receipts from sales of equity or debt instruments of other entities	0.00
Other cash payments to acquire equity or debt instruments of other entities	0.00

Company Results

	Other cash receipts from sales of interests in joint ventures	0.00
	Other cash payments to acquire interests in joint ventures	0.00
	Cash receipts from share of profits of partnership firm or association of persons or limited liability partnerships	0.00
	Cash payment for investment in partnership firm or association of persons or limited liability partnerships	0.00
	Proceeds from sales of property plant and equipment	(48.18)
	Purchase of property plant and equipment	164.86
	Proceeds from sales of intangible assets	0.00
	Purchase of intangible assets	0.00
	Cash advances and loans made to other parties	0.00
	Cash receipts from repayment of advances and loans made to other parties	0.00
	Cash payments for future contracts, forward contracts, option contracts and swap contracts	0.00
	Cash receipts from future contracts, forward contracts, option contracts and swap contracts	0.00
	Dividends received	0.00
	Interest received	166.56
	Income taxes paid (refund)	0.00
	Other inflows (outflows) of cash	(250.98)
	Proceeds from government grants	0.00
	Net cash flows from (used in) investing activities before extraordinary items	(297.46)
	Proceeds from extraordinary items	0.00
	Payment for extraordinary items	0.00
	Net cash flows from (used in) investing activities	(297.46)
5	Cash flows from used in financing activities	
	Proceeds from issuing shares	5,451.51
	Proceeds from issuing other equity instruments	0.00
	Proceeds from issuing debentures notes bonds etc	0.00
	Proceeds from borrowings	3,927.01
	Repayments of borrowings	2,044.86
	Dividends paid	0.00
	Interest paid	396.51
	Income taxes paid (refund)	0.00
	Other inflows (outflows) of cash	0.00
	Net cash flows from (used in) financing activities before extraordinary items	6,937.15
	Proceeds from extraordinary items	0.00
	Payment for extraordinary items	0.00
	Net cash flows from (used in) financing activities	6,937.15
	Net increase (decrease) in cash and cash equivalents before effect of exchange rate changes	3,437.42
6	Effect of exchange rate changes on cash and cash equivalents	
	Effect of exchange rate changes on cash and cash equivalents	0.00
	Net increase (decrease) in cash and cash equivalents	3,437.42
	Cash and cash equivalents cash flow statement at beginning of period	945.69
	Cash and cash equivalents cash flow statement at end of period	4,383.11

Details of Impact of Audit Qualification

Whether results are audited or unaudited			Audited
Declaration of unmodified opinion or statement on impact of audit qualification			Declaration of unmodified opinion
Auditor's opinion			
Declaration pursuant to Regulation 33(3)(d) of SEBI(LODR) Regulation, 2015:The company declares that its Statutory Auditor / s have issued an Audit Report with unmodified opinion for the period on Standalone results			Yes
Sr.No	Audit firm's name	Whether the firm holds a valid peer review certificate issued by Peer Review Board of ICAI	Certificate valid upto
1	M/s. A D V AND ASSOCIATES	Yes	29-02-2028

Audit qualification

Sr.	Details of Audit Qualification	Type of Audit Qualification	Frequency of qualification	For Audit Qualification(s) where the impact is quantified by the auditor	For Audit Qualification(s) where the impact is not quantified by the auditor		
				Management's Views	(i) Management's estimation on the impact of audit qualification	(ii) If management is unable to estimate the impact, reasons for the same	Auditors Comments on (i) or (ii) above
No records available							

Format for Disclosure of Related Party Transactions (applicable only for half-yearly filings i.e., 2nd and 4th quarter)

Amount in (Lakhs)

												Additional disclosure of related party transactions - applicable only in case the related transaction relates to loans, inter-corporate deposits, advances or investments made or the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.									
Sr. No.	Details of the party (listed entity /subsidiary) entering into the transaction	Details of the counterparty		Type of related party transaction	Details of other related party transaction	Value of the related party transaction as approved by the audit committee	Remarks on approval by audit committee	Value of the related party transaction ratified by the audit committee	Date of Audit Committee Meeting where the ratification was approved	Value of transaction during the reporting period	In case monies are due to either party as a result of the transaction		In case any financial indebtedness is incurred to make or give loans, inter-corporate deposits, advances or investments				Details of the loans, inter-corporate deposits, advances or investments				
	Name	Name	Relationship of the counterparty with the listed entity or its subsidiary								Opening balance	Closing balance	Nature of indebtedness (loan/ issuance of debt/ any other etc.)	Details of other indebtedness	Cost	Tenure	Nature (loan/ advance/ intercorporate deposit/ investment)	Interest Rate (%)	Tenure	Secured/ unsecured	Purpose for which the funds will be utilised the ultimate recipient of funds (end use)
1	Hemant Surgical Industries Limited	Hans Kumar Shamji Shah	Managing Director	Remuneration			Approved			30.00	0.00	0.00									
2	Hemant Surgical Industries Limited	Hans Kumar Shamji Shah	Managing Director	Loan			Approved			125.00	0.00	0.00									
3	Hemant Surgical Industries Limited	Hans Kumar Shamji Shah	Managing Director	Loan			Approved			(125.00)	0.00	0.00									
4	Hemant Surgical Industries Limited	Hemant Praful Shah	Whole time Director	Remuneration			Approved			30.00	0.00	0.00									
5	Hemant Surgical Industries Limited	Hemant Praful Shah	Whole time Director	Loan			Approved			14.00	0.00	0.00									
6	Hemant Surgical Industries Limited	Hemant Praful Shah	Whole time Director	Loan			Approved			(14.00)	0.00	0.00									
7	Hemant Surgical Industries Limited	Hemant Praful Shah	Whole time Director	Any other transaction	Rent Paid		Approved			0.90	0.00	0.45									
8	Hemant Surgical Industries Limited	Kaushik Hans Kumar Shah	CFO & Whole time Director	Remuneration			Approved			30.00	0.00	0.00									

9	Hemant Surgical Industries Limited	Kaushik Hanskumar Shah	CFO & Whole time Director	Loan			Approved			3.50	0.00	0.00							
10	Hemant Surgical Industries Limited	Kaushik Hanskumar Shah	CFO & Whole time Director	Loan			Approved			(3.50)	0.00	0.00							
11	Hemant Surgical Industries Limited	Leena Shah	Relative of Director	Remuneration			Approved			4.80	0.00	0.00							
12	Hemant Surgical Industries Limited	Leena Shah	Relative of Director	Any other transaction	Rent Paid		Approved			0.90	0.00	0.45							
13	Hemant Surgical Industries Limited	Mansi Shah	Relative of Director	Remuneration			Approved			6.00	0.00	0.00							
14	Hemant Surgical Industries Limited	Neha Hanskumar Shah	Relative of Director	Remuneration			Approved			15.00	0.00	0.00							
15	Hemant Surgical Industries Limited	Neha Hemant Shah	Relative of Director	Remuneration			Approved			15.00	0.00	0.00							
16	Hemant Surgical Industries Limited	Nehal Vishal Thakkar	Non executive director	Remuneration			Approved			4.05	0.00	0.00							
17	Hemant Surgical Industries Limited	Meenal Patodia	Company Secretary	Remuneration			Approved			1.56	0.00	0.00							
18	Hemant Surgical Industries Limited	Neha Hemant Shah	Relative of Director	Loan			Approved			9.50	0.00	0.00							
19	Hemant Surgical Industries Limited	Neha Hemant Shah	Relative of Director	Loan			Approved			(9.50)	0.00	0.00							
20	Hemant Surgical Industries Limited	Neha Hanskumar Shah	Relative of Director	Loan			Approved			7.58	0.00	0.00							
21	Hemant Surgical Industries Limited	Neha Hanskumar Shah	Relative of Director	Loan			Approved			(7.58)	0.00	0.00							
22	Hemant Surgical Industries Limited	Ikigai Services Private Limited	Common directors	Loan			Approved			2.60	0.00	2.60							
23	Hemant Surgical Industries Limited	Lifesenz Cancer Research Lab Private Limited	Common directors	Loan			Approved			32.38	472.67	505.05							

24	Hemant Surgical Industries Limited	Daiso Diagnostic LLP	Common directors	Loan			Approved			(4.38)	4.38	0.00							
25	Hemant Surgical Industries Limited	Solar Opto Medic Private Limited	Wholly owned subsidiary	Loan			Approved			12.16	3.65	15.82							
26	Hemant Surgical Industries Limited	Lifesenz Cancer Research Lab Private Limited	Common directors	Any other transaction	Rent received		Approved			1.20	0.00	0.00							
27	Hemant Surgical Industries Limited	Hanshik Healthcare	Common directors	Sale of goods or services			Approved			32.65	0.00	53.54							
28	Hemant Surgical Industries Limited	Magnet Medical Private Limited	Common directors	Sale of goods or services			Approved			177.64	0.00	44.92							
29	Hemant Surgical Industries Limited	Magnet Medical Private Limited	Common directors	Purchase of goods or services			Approved			1.97	0.00	2.22							
Total value of transaction during the reporting period										394.43									

Statement on Deviation or Variation for proceeds of Public Issue, Rights Issue, Preferential Issue, Qualified Institutions Placement Etc. (1)

	Amount in (Lakhs)
Mode of Fund Raising	Preferential Issues
Description of mode of fund raising (Applicable in case of others is selected)	
Date of Raising Funds	01-08-2025
Amount Raised	6,152.71
Report filed for Quarter ended	31-03-2026
Monitoring Agency	No
Monitoring Agency Name, if applicable	
Is there a Deviation / Variation in use of funds raised	No
If yes, whether the same is pursuant to change in terms of a contract or objects, which was approved by the shareholders	
If Yes, Date of shareholder Approval	
Explanation for the Deviation / Variation	
Comments of the Audit Committee after review	
Comments of the auditors, if any	

Objects for which funds have been raised and where there has been a deviation, in the following table:

Sr.	Original Object	Modified Object, if any	Original Allocation	Modified allocation, if any	Funds Utilised	Amount of Deviation/Variation for the quarter according to applicable object	Remarks if any
1	Capital expenditure towards development/setting up of new facilities and expansion of existing manufacturing facilities including strategic acquisition/investment	NIL	5,000.00	0.00	409.36	0.00	Textual Information(1)
2	Augment working capital needs of the Company and its Subsidiaries	NIL	1,500.00	0.00	1,500.00	0.00	
3	Repayment of debt	NIL	1,700.00	0.00	1,700.00	0.00	
4	For general corporate purposes	NIL	1,054.27	0.00	1,054.27	0.00	

Text Block

Textual Information(1)	The balance amount of Rs. 1489.07 lakhs is currently lying in company's bank account
--	--

Signatory Details

Name of signatory	KAUSHIK HANSKUMAR SHAH
Designation of person	Chief Financial Officer
Place	MUMBAI
Date	15-05-2026